43results about How to "Reduce the probability of binding" patented technology

The invention discloses a lateral reciprocating immunochromatography method for detecting biological samples and a diagnosis test strip and a diagnosis device based on the method. The diagnosis device comprises a card bottom, a card cover and a diagnosis test strip, wherein the diagnosis test strip comprises a PVC (Polyvinyl Chloride) plate, and a sample layer, a mark layer, a coated film, a water absorbing layer, a buffer solution sample layer and a water-proof isolating film which are stuck to the PVC plate; the surface of the water absorbing layer is covered with the water-proof isolating film and the sample layer in sequence; the water-proof isolating film is easy to extract; the buffer solution sample layer, the mark layer, the coated film and the water absorbing layer are stuck in sequence along a horizontal extraction direction of the water-proof isolating film; the water absorbing layer and the coated film are not overlapped with each other; and the card cover is respectively provided with a liquid dripping window, an observation window and a sample window at positions corresponding to the buffer solution sample layer, the coated film and the sample layer respectively. The diagnosis device disclosed by the invention is applied to reciprocating immunochromatography, and an antigen or an antibody in a sample undergoes a secondary reaction with antibodies or antigens of T and C lines on the coated film, so that the antigen and antibody reaction time is increased, and the sensitivity is increased by 50-100 times than the conventional unidirectional chromatography test strip.

The invention relates to the technical field of biology, in particular to a nano-antibody GN1 specifically combined with a GPC3 protein. The nano-antibody GN1 is composed of a variable region of a heavy-chain antibody, the variable region of the heavy-chain antibody comprises an antigenic determinant complementary region and a skeleton region, the skeleton region is selected from the group consisting of FR1, FR2, FR3 and FR4 and homologous sequences thereof, the antigenic determinant complementary region is selected from the group consisting of CDR1, CDR2 and CDR3 and homologous sequences thereof, the amino acid sequences of the CDR1 to the CDR3 are shown in the formulas of SEQ ID NO. 1 to SEQ ID NO. 3, the amino acid sequences of the FR1-4 are shown in formulas of SEQ ID NO. 4-7, the amino acid sequence of the antibody is shown in the formula of SEQ ID NO.8, and the nucleotide sequence for encoding the amino acid is shown in the formula of SEQ ID NO.9. The nano-antibody GN1 can be specifically combined with hepatoma carcinoma cells highly expressing the GPC3 protein to inhibit hepatoma carcinoma cell proliferation. The amino acid sequence of the nano-antibody GN1 or the nucleotidesequence of the nano-antibody GN1 or the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 or the recombinant cell containing the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 can be applied to research and development of diagnostic reagents and drugs for treating liver cancer.

The present invention, which belongs to the electronic soldering technology field, discloses an in-situ alloying lead-free solder and a preparation method thereof. The present solder consists of two or more alloy powders or single-substance metal powders, which are mixed mechanically and uniformly. In welding and application processes, the solder has the advantages of a strong anti-collapsing ability, a bright co-center circles of the solder joint, a good spreading effect, a simple preparation technique and low cost and the optimal advantages are that the welding with the use of a unified SMT welding technique and without changing the welding technique line and parameters of the previous solder is convenient. The medium / high temperature solder can be welded under a low temperature or gradient temperatures so that the medium / high temperature application of the low temperature solder is realized and the service life of the solder joint is prolonged.

The invention discloses a thermal barrier coating with a thermal barrier and an anti-CMAS corrosion attachment and a preparation process of the thermal barrier coating. The thermal barrier coating isof a double-layer structure and comprises the anti-CMAS corrosion adhesive layer and a thermal insulating layer. The thickness of the thermal insulating layer close to a base body is 30%-60% of the total thickness of the thermal barrier coating, and the thickness of the anti-CMAS corrosion adhesive layer close to thermal current is 40%-70% of the total thickness of the thermal barrier coating. Thethermal insulating layer and the anti-CMAS corrosion adhesive layer are both formed by stacking sheet layers. The sheet layers of the anti-CMAS corrosion adhesive layer can be peeled layer by layer.In the service process of the coating, by means of the large stacked sheet layers, the permeating path of CMAS is obviously increased, the speed of permeating along surface defects of the CMAS is delayed, and the anti-CMAS corrosion capacity of the coating is improved; and on the other hand, the film thermal mismatch stress generated by the temperature change can trigger local layer peeling of theanti-CMAS corrosion adhesive layer, therefore CMAS sediment adhering to the surface of the thermal barrier coating can be removed so that air film hole blockage caused by deposition, near air film holes, of the CMAS can be removed, and the long-time service stability of aero-engine hot end metal components can be greatly improved.

The invention provides a nimodipine submicron emulsion injection and a preparation method thereof. The invention adopts nimodipine of effective dose as a drug and contains pharmaceutic adjuvant such as oil phase, an emulsifier, an auxiliary emulsifying agent, a pH regulator, and an iso-osmotic regulator; the nimodipine, the emulsifier; the auxiliary emulsifying agent and oil used for injection are weighed according to the formula amount, stirred and dissolved in a water bath, added with water used for injection and the iso-osmotic regulator and the like, and fully mixed and emulsified; the pH value of the solution is regulated and the solution is added with the water used for injection until the specified cubage; a high-pressure homogenizer is used for carrying out homogenization for a plurality of times until specified granularity is realized; a filtering membrane of 0.22 Mum is used for filtering and sterilizing; and nitrogenization, subpackaging and sterilization are carried out, and the nimodipine submicron emulsion injection is obtained. The nimodipine submicron emulsion injection of the invention does not contain auxiliary cosolvents, such as benzoic alcohol, polyethylene glycol, and the like, and has the advantages of high drug-load rate and packaging efficiency, slow release of drugs, good stability, and the like. The preparation process is simple, and a preparation which does not contain any organic solvent is provided, thus radically eliminating the defects of organic solvents, separating out no drugs, reducing the work load of medical care personnel and eliminating the psychological burden of the medical care personnel and patients; in addition, the nimodipine submicron emulsion injection has low cost and stable quality and is suitable for industrialized large scale production.

By introducing a multimerized structural domain into a repressor protein and optimizing the number of operator loci interacting with the repressor protein in the preferred embodiment, the invention obtains the repressor protein, a regulatory element group and a gene expression regulation system which have ultrasensitive regulation performance.

The invention relates to cannabidiol compositions and application thereof. Specifically, the invention relates to a cannabidiol composition containing cannabidiol and a surfactant. The composition cansignificantly improve the water solubility of cannabidiol to make cannabidiol to be better applied in the fields of medicine, daily chemical, food, health products and the like.

An information medium which is capable of maintaining the protection capability by a lubricant for a long term. An information medium has a recording area and a non-recording area disposed on at least one surface of a disk-shaped base plate. The information medium is configured such that a lubricant exists on the one surface of the disk-shaped base plate. The recording area is configured such that a protective film formed of DLC exists above the recording layer. At least a surface-side portion of the non-recording area is formed of a resin material having a higher bonding ratio with respect to the lubricant than that of DLC.

The invention relates to a method and a sensor device (100) for the detection of magnetic particles (M) in a sample. The magnetic particles (M) can bind to binding sites (Z) at a binding surface (12), where they can be detected by a detection unit (13, 14). A controller (15) is provided for controlling magnetic attraction (B) of the magnetic particles (M) towards the binding surface (12) in dependence on the detection signal (S) of the detection unit (14) in such a way that rotational relaxation conditions for the magnetic particles (M) are changed. In particular, this change can be controlled to maximize the binding of magnetic particles (M) to the binding surface (12) within a given measurement time. The change can for example be achieved by repeatedly switching the magnetic attraction off for prolonged periods, giving the magnetic particles (M) better chances to orient properly with respect to the binding surface (12).

The invention discloses a stable butylphthalide sodium chloride injection as well as a preparation method and application thereof, belongs to the technical field of pharmaceutical preparations, and solves the problems of poor safety and stability of the butylphthalide sodium chloride injection in the prior art. The stable butylphthalide sodium chloride injection comprises a sulfobutyl betacyclodextrin sodium compound, sodium chloride and water. The pH value of the butylphthalide sodium chloride injection is 4.0-5.0. The preparation method comprises the following steps of weighing a prescription amount of sulfobutyl betacyclodextrin sodium, and adding water for dissolving to prepare an auxiliary material solution; weighing a prescription amount of butylphthalide, adding the butylphthalide into the auxiliary material solution, stirring to enable the sulfobutyl betacyclodextrin sodium to include the butylphthalide, and adjusting the pH value of the solution to 4.0-5.0 after the inclusionof the butylphthalide is completed; and filtering, filling and sterilizing to obtain the product. The stable butylphthalide sodium chloride injection as well as the preparation method and applicationthereof are scientific in design and ingenious in thought, and the butylphthalide sodium chloride injection has good stability and safety.

A compound useful as an AMPK-activating agent is provided. A compound represented by formula (I) (wherein X represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group or a substituted or unsubstituted heterocyclyl group; R1 represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkylsulfinyl group, a substituted or unsubstituted alkylsulfonyl group or a substituted or unsubstituted alkyloxycarbonyl group; R2 represents a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group or the like; R3 represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group or the like; and R4 represents a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group or the like) or a pharmaceutically acceptable salt thereof.

The invention discloses an anti-fake ink which comprises the following components in parts by mass: 50-80 parts of a prepolymer, 10-20 parts of a composite photoinitiator, 20-30 parts of carboxylatedFe3O4 magnetic nanoparticles, 10-20 parts of hydrophobic gaseous silicon dioxide, 1-5 parts of an amphiphilic surfactant and 10-20 parts of a fluorescent pigment. The anti-fake ink is good in identification performance, magnetic nano-iron tetroxide particles are dispersed evenly, and the anti-fake ink is resistant to rubbing without degaussing.

Provided is a compound useful as an AMPK activator. A compound represented by formula (wherein R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group; R1, R2 and R3 independently represent a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, or the like, wherein a case in which R1, R2 and R3 represent a hydrogen atom simultaneously is excluded; X represents a single bond, -S-, -O-, -NR5-, -C(=O)-, or the like; R5 represents a hydrogen atom, or a substituted or unsubstituted alkyl group; and Y represents a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, or the like), or a pharmaceutically acceptable salt thereof.

The invention relates to a micro-gel ball whitening essence and a preparation method thereof, which aims at providing a micro-gel ball whitening essence with the advantage that the whitening componentcan be slowly released at the surface of skin and can deeply permeate into the skin keratoderma. The micro-gel ball whitening essence is prepared from the following components of a phase A: a properamount of deionized water; a phase B1: 3 to 7% of skin moisturizer, and 0.005 to 0.05% of acrylate / C10-30 alkyl acrylate crosslinking polymer; a phase B2: 2.3 to 11% of skin moisturizer; a phase B3: 0.01 to 0.5% of whitening and freckle removal agent; a phase C1: 0.02 to 0.6% of anti-inflammatory agent, 7.9 to 22.8% of moisturizer, and 0.1 to 2% of whitening and freckle removal agent; a phase C2:a proper amount of deionized water, and 0.1 to 0.5% of suspension agent; a phase C: a proper amount of deionized water, and 0.01 to 0.014% of pH (potential of hydrogen) regulator; a phase C4: a properamount of deionized water, and 0.1 to 3.0% of whitening and freckle removal agent; a phase D: 0.01 to 2% of whitening and freckle removal agent. The invention belongs to the technical field of skin-care cosmetics.

Provided is a compound useful as an AMPK activator. A compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate of the same. In formula (I), the moiety represented by (II) is (III); R1s independently represent halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like; m is an integer of 0-3; R2 represents hydrogen or substituted or unsubstituted alkyl; X represents -O-; and Y represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

The invention relates to a quickly dissolved film. The film is characterized by consisting of 0.01 to 90 percent of frovatripan serving as an active ingredient and the balance of film forming material and medicinal auxiliary materials. A preparation method comprises the following steps of: dissolving frovatripan and polymer in water or organic solvent or suspending other auxiliary materials, coating the solution on silicon rubber paper or a proper carrier, and drying for 0.5 to 4 hours at the temperature of between 35 and 65 DEG C; and performing shearing or film pressure separation on the dried semi-finished product to obtain the film of the specified size.

The invention discloses a beneficiation method of mixed copper ore having a low oxidation rate and a high binding rate. With the respect to sulfide-oxidized mixed copper ore having a low oxidation rate and a high binding rate, copper sulphide ore and free copper oxide ore in the sulfide-oxidized mixed copper ore are recovered through floatation, flotation concentrate is subjected to desulphurizing roasting and copper oxide concentrate is obtained, roasting flue gas is used for leaching out refractory copper oxide and binding copper in flotation tailings, then copper ions in ore pulp are leached out by sodium sulfide sediment tailings and copper sulphide sediment is obtained, xanthate is added for the floatation of the copper sulphide sediment and copper sulphide concentrate is obtained, the cupric sulfide concentrate and sulfide-oxidized mixed copper concentrate are mixed, then a mixture is subjected to the desulphurizing roasting and final copper oxide concentrate is obtained. According to the method, the low-grade tailings are leached out by sulfur dioxide generated by sulfur in the concentrate of the mixed copper ore, refractory free copper oxide and bound copper, which are difficult to recover, in the flotation tailings are recovered, the cost is low, and a comprehensive recovery rate of copper is raised significantly.

The present invention provides an organic bioelectronic HD device system for the effective removal of protein-bound substances, comprising PEDOT:PSS, a multiwall carbon nanotube, polyethylene oxide (PEO), and (3-glycidyloxypropyl)trimethoxysilane (GOPS). The composite nanofiber platform exhibited (i) long-term water-resistance; (ii) high adhesion strength on the PES membrane; (iii) enhanced electrical properties; and (iv) good anticoagulant ability and negligible hemolysis of red blood cells, suggesting great suitability for use in developing next-generation bioelectronic medicines for HD.

The invention belongs to the technical field of quantum dots, and particularly relates to a quantum dot film, a preparation method thereof and a QLED device. The quantum dot film contains quantum dots, a thiol ligand is combined to the surfaces of the quantum dots, and anions are also combined to the surfaces of the quantum dots. According to the invention, the surfaces of quantum dots in the quantum dot film are combined with the anions; therefore, the binding rate of the thiol ligand and the metal elements on the surfaces of the quantum dots can be effectively reduced, the surface defects caused by the fact that the thiol ligand on the surfaces of the quantum dots flows to drive metal atoms on the surfaces of the quantum dots to flow are effectively reduced, the fluorescence intensity ofthe quantum dot film is improved, and the luminous efficiency of the device is improved.

The invention belongs to the technical field of concrete admixtures, and particularly relates to a high-efficiency water reducing agent for high-strength concrete. The high-efficiency water reducing agent is prepared from, by weight, 3-6 parts of polyglyceryl-10 myristate, 5-8 parts of sodium tripolyphosphate, 2-5 parts of sodium polyacrylate, 4-9 parts of sodium dodecylbenzene sulfonate, 10-12 parts of hydrolyzed polymaleic anhydride (HPMA), 3-7 parts of zinc salt, 5-12 parts of maltodextrin, 5-10 parts of N,N'-dinitrosopentamethylenetetramine, 5-10 parts of azodicarbonamide, 3-4 parts of N,N-dimethylcyclohexylamine, 6-8 parts of polyacrylamide (PAM), 15-20 parts of hydroxyethyl cellulose, 8-16 parts of sodium carboxymethylcellulose, 13-20 parts of a naphthalenesulfonate formaldehyde condensate and 3-6 parts of an auxiliary agent. The water reducing agent has various types of hydrophilic groups, high water-reducing efficiency and good fluidity, can obviously improve the fluidity of the concrete, has a remarkable early strengthening effect after final setting, and can significantly improve the strength of the concrete at various ages.

The invention relates to a black arsenic poisoning SCR denitration catalyst regeneration method, in particular to a catalyst cleaning process for efficiently removing black arsenic by a cleaning solution with a neutral pH value. The invention aims to provide the black arsenic poisoning SCR denitration catalyst regeneration method. Under the condition that the pH value is neutral, the black arsenicon the surface of the SCR denitration catalyst is removed to the greatest extent, the original mechanical strength of the catalyst is not reduced, the loss of active components of the cleaned SCR denitration catalyst is reduced as much as possible, and certain anti-poisoning additives are implanted to enable the catalyst to have certain anti-black arsenic poisoning capability.

The invention discloses a bexarotene conjugate, a drug composition and application thereof. The drug composition comprises the bexarotene conjugate or a medicinal composition of the bexarotene conjugate and a pharmacodynamics acceptable carrier and is a liquid preparation, a solid preparation, a semi-solid preparation, a capsule preparation, a granule preparation, a gel preparation and an injection preparation. The drug composition is nano granules or lipidosome prepared by the bexarotene conjugate or the bexarotene conjugate and additives, and the particle size is 10 to 1000 nm. The bexarotene conjugate and the nano granules thereof can be used as liquid preparations, solid preparations, semi-solid preparations, sterilized preparations and sterile preparations, are low in toxicity and can be used for treating tumors and treating or preventing alzheimer diseases.

The invention discloses a flavonoid compound composition and a preparation method thereof. The flavonoid compound composition comprises a flavonoid compound, an absorption slow-release substance and asolubilizer. According to the invention, the absorption slow-release substance and the solubilizer are added into the flavonoid compound to form the composition, so that the water solubility of the flavonoid compound is improved, and the bioavailability is improved; and the cell damage is reduced at the same time, compared with single flavonoid compound administration, the cell viability is improved by at least 1.17 times, which shows that the composition can effectively reduce the cytotoxicity.

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I): L represents NR2R3, SR7, SO2R8, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkenyl; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or the like; R3 represents a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or the like; R7 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or the like; R8 represents a hydrogen atom, a substituted or unsubstituted alkyl (but not an unsubstituted methyl or an unsubstituted ethyl), a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or the like; Y represents a substituted or unsubstituted alkyl (but not an unsubstituted methyl or an unsubstituted ethyl), a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted aryl, or the like; Z represents -CR6= or -N=; R1 represents a hydrogen atom or a substituted or unsubstituted alkyl; and R4, R5, and R6 are each independently a hydrogen atom, a halogen, a hydroxyl, a cyano, a nitro, a carboxy, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or the like.